LOS ANGELES--(BUSINESS WIRE)--A coalition of AIDS advocates, spearheaded by AIDS Healthcare Foundation, have sent a letter today to the CEO of HIV/AIDS drug maker Gilead Sciences, Inc.—John C. Martin—urging the company not to “decimate ADAP [AIDS Drug Assistance Programs]” by pricing its latest HIV/AIDS drug combination—known as the “Quad”—higher than Gilead’s Atripla, the most prescribed HIV/AIDS medication.
